Vestipitant

Vestipitant
Systematic (IUPAC) name
(2S)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide
Identifiers
CAS Number 334476-64-1 YesY
ATC code None
PubChem CID 9832383
IUPHAR/BPS 5757
ChemSpider 8008111
UNII S052TOI9BI N
ChEMBL CHEMBL522987 N
Chemical data
Formula C23H21F10N3O
Molar mass 545.416 g/mol
 NYesY (what is this?)  (verify)

Vestipitant is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK1 receptor. It is under development as a potential antiemetic and anxiolytic drug,[1][2] and as a treatment for tinnitus[3] and insomnia.[4]

See also

References

  1. ↑ Reddy, GK; Gralla, RJ; Hesketh, PJ (2006). "Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis". Supportive cancer therapy 3 (3): 140–2. doi:10.3816/SCT.2006.n.011. PMID 18632487.
  2. ↑ Brocco, M; Dekeyne, A; Mannoury La Cour, C; Touzard, M; Girardon, S; Veiga, S; De Nanteuil, G; Dejong, TR; et al. (2008). "Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents". European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 18 (10): 729–50. doi:10.1016/j.euroneuro.2008.06.002. PMID 18657401.
  3. ↑ Clinical trial number NCT00394056 for "Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss" at ClinicalTrials.gov
  4. ↑ Ratti, E; et al. (December 2013). "Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia.". Sleep (2013) 36 (12): 1823–30. doi:10.5665/sleep.3208. PMC 3825431. PMID 24293756.
This article is issued from Wikipedia - version of the Monday, October 12, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.